Resumo: O artigo apresenta um histórico sobre a descoberta de novos fármacos e alguns dos cientistas pioneiros dessas descobertas. Descreve a cadeia de inovação em fármacos, os desafios e as contribuições do INCT-INOFAR para que o Brasil, a exemplo dos países do grupo G-8, seja um player no desenvolvimento de fármacos.
Final Considerations Preamble
Innovation is a complex process which is based on the application of scientific knowledge into processes leading to products and goods with a high technological level (e.g. pharmaceuticals, computers, scientific instruments, airplanes, etc.). These products were responsible for 25% of the world trade in the beginning of this century, and its production is mainly restricted to developed nations, the ones that make up the G-8 Group. As this is a wide topic, it will be dealt in a concise way and will be limited to the issue of innovation in pharmaceuticals. 1 Industrialized drugs, more so than any other technological good, demand high scientific and technological knowledge in their invention /creation, in all the steps of this translational process, starting from the research laboratory bench to the chemicalpharmaceutical industrial factory. High sums of resources are necessary until the medications reach drugstore shelves. The reward for pharmaceutical companies who develop new pharmaceuticals is the profit they provide. For countries like Brazil, with no tradition in the development of new pharmaceuticals, and in the current stage of our pharmaceutical industry, if invention is difficult, innovation is possible.
For making easier the understanding of the topic of drug innovation, we will consider the following items
Historic Chronology
The pharmaceuticals as industrial products and goods began with acetylsalicylic acid (ASA) in the latter days of the XIX century when Felix Hoffman successfully obtained it in 1897, in its pure form, reproducing what French chemist Charles Gerhardt had obtained in 1853, as an impure product, in the acetylation of salicylic acid. In the early XX century, several pharmaceuticals with various therapeutic indications were created.
2 Figure 1 illustrates the timeline for the discovery / invention of certain drugs.
In a careful analysis of Figure 1 , one observes that many of the listed drugs have represented great therapeutic innovations, although many of these pioneer molecules have been for the most part supplanted in terms of safety and efficacy. The lack of knowledge of the pharmacological mechanism of action (MOA) is a common important aspect to note in the drugs created in the first two decades of the XX century, as it was the case with salvarsan 3 and penicillin, both being included in the class of chemotherapeuticals. This reality persisted until the second half of the century, when pharmacology started to stand as a subject. Invented by Sir James W. Black (1924 Black ( -2010 ; Figure 4 ), 7 at the industrial research laboratories of the Imperial Chemical Industries (ICI), in London, England, in 1965, this pharmaceutical, the first antihypertensive acting as a -blocker, is a significant example of the application of the so-called basic research, recognized by the genius of Black who was awarded the Nobel Prize in Physiology and Medicine, in 1988, after having invented cimetidine, another innovative pharmaceutical. Cimetidine (Figure 3) 8 was the first selective antagonist of the sub-type 2 of histaminergic receptors with an indication for the treatment of peptic ulcer, also being the first blockbuster in the history of pharmaceuticals, reaching US$ 1 billion in yearly sales in the 1980s. Figure 5 ), were not enough to assure that, when the first half of last century was over, the first antibiotic represented by G-penicillin was released for therapeutic use. This was a medicinal mark that would revolutionize the treatment of bacterial infections. Without the initiative of pharmaceutical industries to fund, at that time under risk, the necessary studies for the isolation, purification, and production of the active principle of a microbial nature described for the first time in 1928, by Fleming, would remain as an academic curiosity. The discovery of penicillin, unstable when administered orally, allowed for the studies in the pharmaceutical use of its injectable form. In the few examples mentioned herein ( Figure 3 ), it is observed that all three drugs were the first ones of their therapeutic classes, inspiring other incremental innovations, which joined these pioneers drugs.
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There are several -lactamic antibiotics, -blocker antihypertensive or H-2 antagonists that are now available.
Considering that only these drugs ( Figure  3 ) are truly innovative, being the first ones of natural origins and the following ones synthetic, it is impossible to quantify their therapeutic impact in terms of number of saved lives ever since. The cure of infections that were previously lethal and the control and reduction of morbidity of arterial hypertension, a chronic non-communicable disease, silent and sneaky, treated by penicillin and propranolol could be symbols for the impact of innovative drugs for the improvement of the quality of life for humankind. 13 Carefully inspecting the timeline of the discovery of pharmaceuticals of Figure 1 
Pharmaceutical technological innovation: Pasteur's Quadrant
Throughout the years, after the World War II, there were many studies carried out for attempting to improve the social profits of investments in science and technology (S&T). Among the authors who have devoted about this question is Donald Stokes (1927 Stokes ( -1997 , 14 an American political scientist from the University of Princeton, USA, who published, in 1997, the book "Pasteur's Quadrant: Basic Science and Technological Innovation" (Figure 7 ).
14 In his book he established a dialogue between basic and applied sciences. He has named the quadrant that results from the effective application of scientific knowledge as the Pasteur's Quadrant (Figure 7 ). The reading, even if brief, of the quadrants illustrated in Figure 7 , allows to understand that drugs might be the most significant example of the importance of basic knowledge to be applied in industrial products that might significantly benefit the society, and which occupy the quadrant named Pasteur, where the so-called basic sciences were coupled with the applied sciences.
Recent published works have indicated that the current conception guiding the scientists thoughts involved in the processes of discovery / invention of new innovative drugs, that have high market impact, is based on technologies that stimulated new local developments and in the application of basic scientific concepts, not rarely coming from universities, which allow the election or choice of original therapeutic targets, resulting in effective and valuable therapeutic innovations. 15 In this context, it is worth noting that the world pharmaceutical sector has surpassed US$ 890 billion in sales in 2011, 16 out of which, according to innovative pharmaceutical companies, 10 to 15% a year is invested in R&D. These Big Pharmas have in their portfolio, under patent processes, authentic billionaire molecules with yearly gross profits of sums up to 2 digit in the billion dollar category, thanks to the large funding for research that allows these significant therapeutic innovations to come to fruition, coupled with the effective and continuous marketing and advertising work, which might be responsible for another 15% of their yearly gross profits. Figure 8 exemplifies 18 The USA is the main market for medication innovation, which also has the greatest volume of sales throughout the world. We have identified, each year, those which have become authentic blockbusters in terms of world sales, like esomeprazole, released in 2000, which has not only supplanted the all time best-selling drug, atorvastatin, a drug due to Pfizer that has kept 2 digit billionaire worldwide sales for over a decade, ending its monopoly period with sales, in 2011, of around US$ 13 billion, with probable total worldwide sales during its patent protection period of US$ 135 billion, between 1991 and 2011. 
The capacity for innovation in the Pharmaceutical Industry (PI)

Contemporary innovative pharmaceuticals
Several specialists have pointed out that the current stage of reduced innovative capacity by the Big Pharmas, 19,20,21 illustrated in Figure  8 , may have several different diagnoses, made by distinct specialists, in many publications, all agreeing on one point: the loss of innovative capacity by the pharmaceutical industry has been significant in the last decade, considering the average of ca. 20 releases per period, with a slight increase in 2011.
Somehow, there is a certain coincidence between the different approaches used in these diagnoses, indicating that the model for managing pharmaceutical innovation used so far successfully by the industry, has now been made less useful by its complexity (Figure 9 ). The fusions and mergers that have recently taken place in several large pharmaceutical companies, which have made the management of their research centers especially challenging, due their large geographical distribution as well as the flow of large volumes of scientific information generated by these activities. 22 There has also been, as another factor, the frustration of the sector, which did not achieve the expected success in the adoption and implementation of new research techniques for new pharmaceutical candidates with the application of integrated combinatory chemistry to high-throughput screening (HTS), for example. 23 Combinatory chemistry, in which a random assembly of construction blocks or molecular fragments is constructed, was a great hope for the pharmaceutical industry, but did not yield the expected results. These factors, whether isolated or combined, have contributed for the lower innovative capacity of pharmaceutical industries. This reality has forced the adoption of new models of pharmaceutical innovation management in PIs, such as open innovation, which has allowed the chain of radical innovation to take on a new face, as illustrated in Figure 10 . Table  1 are examples of expressive therapeutic innovations in different therapeutic classes, like chemotherapeutics of continuous use, up to the discovery of tofacitinib (Figure 11) . 25 This is an immunomodulator released by Pfizer for the treatment of chronicdegenerative inflammatory illnesses like rheumatoid arthritis, which is the first inhibitor of Janus kinase 3 (JAK3) to be used therapeutically, approved in November 2012, by the FDA-USA. (Figure 13) , 28 an important pharmaceutical that is a tyrosine-kinase inhibitor with usage in the treatment of several types of cancer. Sunitinib, due to its high price, has an expressive impact on the Unified Health System (SUS) of Brazil. Another generic drug synthesized in the Institute of Chemistry at UNICAMP by Professor Dias, was fluoxetine, 29 a potent neuroactive agent, used in the treatment of anxiety ( Figure 13 ). The synthesis of the substances illustrated in Figure 13 represents a great milestone in Brazilian medicinal chemistry, the first of many that might follow, achieved by the efforts of INCT-INOFAR.
In radical innovation activities, INCT-INOFAR has identified several attractive substances that are authentic candidates to prototypes of new drugs in different therapeutic classes, all of which are documented in its yearly activity reports (Figure 14) 27b,29 and in the special issue of the Revista Virtual de Química dedicated to INCT-INOFAR ( Figure 15) . 30 In its portfolio of research projects are included the molecular design, synthesis and evaluation of new analgesic compounds, especially focused on neuropathic pain. Also new anti-inflammaty prototype that act through new dual pharmacological mechanisms, capable of being effective in the treatment of severe chronic conditions, as obstructive pulmonary disease (COPD) are included in the research projects portfolio. New neuroactives compounds that might allow the control of cognitive conditions, antiparasitic agents for the treatment of neglected diseases like leishmaniasis, antiproliferative drugs that may be used in the treatment of cancer, and substances of interest in the treatment of cardiovascular diseases, like inotropic agents and vasodilators. 30 Countless results have been achieved in several interdisciplinary research subprojects, which, due to confidentiality, may not be discussed here. 
Final Considerations
What about the future? The independence of a nation depends more and more on its ability to offer access to medication to its citizens. Brazil is now the 7 th world economy, and maintaining its position or going higher in this rank demands a strong and innovative pharmaceutical industry that should not be limited to import active principles from China and India. To give up on the development of new innovative drugs is to give up on sovereignty, and to remain in the BRIC's when the goal for a nation as rich as Brazil is to be a part of the G-8.
In tune with the present President of the Republic of Brazil, Dilma Roussef, who in the General Assembly of the United Nations Organization, in New York, on September 19th of this year, said that "... the defense of access to medication and prevention should walk side by side", the INCT-INOFAR members believe that it is possible, in the next 10 years, for the creation of novel synthetic drugs and the acceleration of the development of new original routes for future generic drugs that will have their patents expired. For this to come true, the investment in consolidated research groups needs to continue, so that goals are not only the publishing of scientific papers, but also that these groups can establish solid partnerships with national entrepreneurs, always respecting the individuality of each partner. The discovery of new drugs will take place though these partnerships.
In its short existence, INCT-INOFAR has shown that it is possible to achieve a Brazilian drug, one that "speaks" our language, the Portuguese. Making feasible the creation of pharmaceuticals will depend on continuous funding and public-private partnerships. INCT-INOFAR is the best example that Brazil can become a player in the world pharmachemical market. Maintaining this organization it is also a responsibility of the funding agencies. Gather a group of active and qualified researchers throughout the country was not an easy task. However, separating them does not take a lot of energy, as is proven by the second law of thermodynamics and their sustentability is the next challenge. In the academy it is possible to find high scientific quality, what is needed is continued funding for Brazil to become, as example of developed countries, a country with strong pharmaceutical industry and qualified to the discovery and development of new innovative drugs to treat its population.
